# GC&H Investments

> GC&H Investments is a VC fund in San Francisco backing Biotechnology and Health Care. See 23 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 23
- Last investment: Jun 2026
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/gch-investments

GC&H Investments is a VC fund in San Francisco focused on Biotechnology and Health Care. GC&H Investments operates as a venture capital firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 30% |
| Health Care | 6 | 26% |
| Medical | 4 | 17% |
| Information Technology | 4 | 17% |
| Software | 3 | 13% |

38 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 9 | 39% |
| Series A | 4 | 17% |
| Series B | 4 | 17% |
| Venture - Series Unknown | 2 | 9% |
| Pre-Seed | 1 | 4% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 17 | 74% |
| China | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lium | Lium provides a platform that structures technical datasets and makes them accessible through natural language, enabling teams to analyze, understand. | $5.5M | Seed | Jun 10, 2026 |  |
| Inferact | The aim of Inferact is to make vLLM the leading AI inference engine in the world and advance AI by lowering the cost and speed of inference. | $150M | Seed | Jan 22, 2026 |  |
| Iolyx Therapeutics | Iolyx Therapeutics is a biotechnology research and healthcare service provider for ocular diseases. | $15M | Series B | Dec 03, 2025 |  |
| Pave Bank | The world's first multi-asset and programmable bank | $39M | Series A | Oct 23, 2025 |  |
| Canvas | Canvas scans the areas using an iPad or iPhone and then turns them into 3D designs. It enables remodelers, architects, interior designers, and contractors to create editable, layered as-built models. | $10M | Series A | Jan 29, 2025 |  |
| TwoStep Therapeutics | TwoStep Therapeutics is developing novel tumor-targeting therapeutics for solid tumors. | $6.5M | Seed | Jun 25, 2024 |  |
| Particle.News | Particle. News helps in developing an AI-based news reader that would provide users with personalized news flows. The service is still in the private beta stage. | $10.9M | Series A | Jun 11, 2024 |  |
| HyperSpectral | Hyper Spectral | $12.1M | Series A | Jun 05, 2024 |  |
| Seismic Therapeutic | Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements ofbiologics drug discovery – structural biology, protein engineering, and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. | $121M | Series B | Dec 04, 2023 |  |
| BioLoomics | BioLoomics is a preclinical stage biotechnology company that uses evolution in a microscope to develop drug discovery tools and protein drugs. Our VariVolve platform tests millions of protein designs for a targeted activity in hours, enabling efficient mining of the vast chemical space of protein designs. A strong advantage of our approach is theuse of whole intact cells as test vessels that capture complex drug behavior not attainable in conventional assays. | $8.7M | Seed | Sep 19, 2023 |  |

10 of 23 investments shown.

## Co-investors
- [Lightspeed Venture Partners](https://shizune.co/investors/profile/lightspeed-venture-partners) — VC Fund, 5 deals together
- [VITALIZE Venture Capital](https://shizune.co/investors/profile/vitalize-vc) — VC Fund, 3 deals together
- [Accel](https://shizune.co/investors/profile/accel) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Bloomberg Beta](https://shizune.co/investors/profile/bloomberg-beta) — VC Fund, 2 deals together
- [C5 Capital](https://shizune.co/investors/profile/c5-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does GC&H Investments invest in?

GC&H Investments invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did GC&H Investments last invest?

The most recent investment recorded for GC&H Investments closed in Jun 2026. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co